EFFICACY AND SAFETY OF NINTEDANIB FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal form of progressive fibrosing interstitial pneumonia with limited treatment options. This disease is not curable, but already there is a treatment that stabilizes the course of the disease and it seems to slow down the progression of the disease. These are two antifibrotic drugs: nintedanib and pirfenidone. In this article data from clinical studies INPULSIS, TOMORROW and INPULSIS-ON are reviewed. According to them, nintedanib slows down the progression of the disease at least up to 3 years and reduces the rate of exacerbations. Nintedanib is well-tolerated and safe to use. Diarrhea is the most frequent side effect, associated with the usage of nintedanib.